Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Genitourinary Cancers
What bowel dose constraint do you recommend if you are boosting a pelvic lymph node for prostate cancer?
Do you have a maximum bowel dose constraint?
Answer from: Radiation Oncologist at Community Practice
We generally use 55 Gy to < 5 cc based on Gyne literaturem and try to make sure the high prescribed dose is limited to one wall of bowel loop.
Comments
Radiation Oncologist at Torrance Memorial Medical Center
@Sushil Beriwal, could you share a paper or protoc...
Radiation Oncologist at Varian Medical Systems/Allegheny health network
This is the one I was referring to. It’s a s...
2752
2753
Sign in or Register to read more
Answer from: Radiation Oncologist at Academic Institution
60 to 66 Gy at 2 Gy per fraction.
Sign in or Register to read more
6526
6532
Related Questions
In asymptomatic patients with castrate resistant prostate cancer who have failed chemotherapy and have progressive PSMA-avid vertebral body metastases, when do you prescribe lutetium 177 (Pluvicto) vs prophylactic spinal radiation?
Do distant lymph nodes from metastatic prostate cancer (retroperitoneal and SCV) count as oligometastatic disease?
Are there any contraindications to Pluvicto therapy you personally use, given that there are none directly provided by the manufacturer?
Would you consider re-irradiation for a prostate local failure for a patient who initially received standard fractionation with a focal SIB to 95 Gy, or a SBRT boost with cyberknife after EBRT?
Is there any evidence for amyloid/amyloidosis causing a spurious/false PSA reading?
Do you recommend radiation in a patient with BAP1Tumor Predisposition Syndrome with prior RCC with recurrent brain met after previous resection?
How do you incorporate absolute percent pattern 4 (APP4) into your risk stratification, specifically your recommendation for ADT for intermediate prostate cancer?
Which patients with prostate cancer do you consider to be good candidates for salvage local treatment after radiation therapy?
How do you dose or sequence therapy to overcome radioresistance from oligometastatic disease from RCC?
How do you manage favorable intermediate risk prostate cancer patients that have a PIRADS 5 lesion that was most-likely missed in the template biopsy?
@Sushil Beriwal, could you share a paper or protoc...
This is the one I was referring to. It’s a s...